Cancer caregivers experience high levels of stress related to the caregiving role, particularly for rural caregivers. The purpose of this study is to assess the acceptability and preliminary effect of enCompass Carolina, a social support program for caregivers of rural-dwelling patients with cancer.

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.

Collecting data on chronic GVHD instances

The main purpose of this clinical research study is to assess the safety, tolerability, efficacy (the ability of the study drug to produce the desired anti cancer effect), PK] and PD of GHF009X2101 the study drug in patients with relapsed or refractory hematologic malignancies including AML, CLL, SLL or other lymphomas [including other leukemia].

To determine in a randomized manner whether the addition of levocarnitine prophylaxis to asparaginase-containing regimens will decrease the incidence of conjugated hyperbilirubinemia (>3 mg/dL) during ALL induction therapy in adolescents and young adults (AYAs, age 15-39 years).

To find out if the addition of 2 blocks of inotuzumab ozogamicin to the standard chemotherapy regimen will improve outcomes in children and young adults with High-Risk (HR) B-cell acute lymphoblastic leukemia (B-ALL).

The primary endpoints are to determine the recommended phase 2 dose (RP2D) of SNDX-5613 administered in combination with chemotherapy in patients with relapsed or refractory KMT2A-rearranged (KMT2A-R) acute lymphoblastic leukemia (ALL), and to estimate the minimal residual disease (MRD) negative remission rate of patients with R/R infant KMT2A-R ALL treated with SNDX-5613 in combination with chemotherapy. Secondary endpoints include characterizing the pharmacokinetics (PK) of SNDX-5613 administered with chemotherapy in patients with R/R infant KMT2A-R ALL, estimating the 18-month event-free survival (EFS) of patients with R/R infant KMT2A-R ALL treated with SNDX5613 in combination with chemotherapy, estimating 18-month overall survival (OS) of patients with R/R infant KMT2A-R ALL treated with SNDX5613 in combination with hemotherapy, and characterizing the tolerability of SNDX-5613 given as monotherapy in patients with R/R infant KMT2A-R ALL. The exploratory endpoint is to assess the biologic activity of SNDX-5613 administered with chemotherapy in patients with R/RKMT2A-R ALL.

The purpose of this study is to identify specific barriers to preventing a late stage cancer diagnosis within communities identified in North Carolina as having a higher rate of advanced cancer diagnoses.

The purpose of this study is to create a registry that will collect clinical data from participants attending UNC Hospitals who may present with metastatic cancer and are evaluated to receive radiation therapy. We hope to create a registry that future studies can pull from to study the impacts of radiation therapy on patient cancer outcomes.

This study wants to learn how people with cancer manage their day-to-day health and treatment while receiving medicines for cancer. We will ask patients about their experiences through short surveys and interviews to understand what helps them stay well and avoid emergency visits or hospital stays. The goal is to find ways to better support patients during treatment, especially those who live farther from the hospital or have fewer resources.